

LAW OFFICES
KILYK & BOWERSOX, P.L.L.C.
Intellectual Property Law

RECEIVED
 CENTRAL FAX CENTER
 JAN 11 2008

From the Desk of
LUKE A. KILYK*

400 Holiday Court
 Suite 102
 WARRENTON, VA 20186

FAIRFAX OFFICE
 3603-E Chain Bridge Road
 Fairfax, Virginia 22030

Email: Ikilyk@kbpatentlaw.com
 Website: <http://www.kbpatentlaw.com>

TEL.: (540) 428-1701
 FAC.: (540) 428-1720
 (540) 428-1721

*Admitted only in PA and DC

PLEASE DIRECT CORRESPONDENCE TO OUR WARRENTON OFFICE

FACSIMILE TRANSMISSION COVER SHEET

DATE: January 11, 2008

TO: Examiner Maury A. Audet
 Group Art Unit: 1654
 Mail Stop Amendment
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

RE: U.S. Patent Application No. 10/544,254
 Entitled: MEDICAMENT FOR PREVENTING, INHIBITING
 OR TREATING ADHESION FORMATION
Our Ref.: 3190-081

FROM: Luke A. Kilyk, Esq. 

FAC. TEL. NO.: 1-571-273-8300

NUMBER OF PAGES (INCLUDING THIS COVER SHEET): 5

Items Attached: Second Supplemental Information Disclosure Statement -- 3 pages
 Form PTO-SB-08 -- 1 page

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 1-571-273-8300 on January 11, 2008.

Kim Blum
 Name (Print)

Kim Blum
 Signature

THE INFORMATION CONTAINED IN THIS MESSAGE IS CONFIDENTIAL INFORMATION INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED. This message may also be an attorney/client communication which is privileged and confidential. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by calling us collect and return the original message to us at the above address by mail. Thank you.

RECEIVED
CENTRAL FAX CENTER
JAN 11 2008

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 1-571-273-8300 on January 11, 2008.

Kim Blum
Name (Print)

Kim Blum
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | | | |
|-----------------------|-----------------|---|-------------------|----------------|
| In re Application of: | MIYAZAKI et al. |) | Examiner: | Maury A. Audet |
| | |) | | |
| Application No.: | 10/544,254 |) | Group Art Unit: | 1654 |
| | |) | | |
| Filed: | August 1, 2005 |) | Confirmation No.: | 1342 |
| | |) | | |
| Docket No.: | 3190-081 |) | Customer No.: | 33432 |

For: MEDICAMENT FOR PREVENTING, INHIBITING OR TREATING ADHESION FORMATION

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT PURSUANT TO 37 CFR 1.97(e)(2)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

January 11, 2008

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-SB-08. Pursuant to the current United States Patent and Trademark Office rules, no copies of U.S. Patents/Patent Application Publications are provided.

This Information Disclosure Statement is being submitted after expiration of the three-month period following filing of the above-captioned application but before any Final Office Action or Notice of Allowance.

The undersigned hereby certifies that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was

Second Supplemental Information Disclosure Statement
U.S. Patent Application No. 10/544,254

known to any individual designated in §1.56(c) more than three months prior to the filing of the Information Disclosure Statement.


The above information is presented so that the Patent and Trademark Office can, in the first instance, determine any materiality thereof to the claimed invention. *See* 37 CFR 1.104(a) and 1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents cited in the attached Form PTO-SB-08 be made of record therein and appear on the first page of any patent to issue therefrom.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in this application and applicant determines that the cited documents do not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

It is believed that no fee is required to make this a complete and timely filing. However, if it is determined that a petition or fee is required, the Commissioner is hereby authorized to charge any fee associated with this statement to our Deposit Account No. 50-0925.

Respectfully submitted,



Luke A. Kilyk

Second Supplemental Information Disclosure Statement
U.S. Patent Application No. 10/544,254

Atty. Docket No.: 3190-081
KILYK & BOWERSOX, P.L.L.C.
400 Holiday Court, Suite 102
Warrenton, VA 20186
Tel: (540) 428-1701
Fax: (540) 428-1720
Enclosure: PTO/SB/08a